TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction of SDMA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum E2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum FSH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FMA score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative force to dilate the cervix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unbound systemic exposure of ixazomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total systemic exposure of ixazomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3 drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: symptom relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SASS (Self-Assessment of Subjective State)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral vasoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma concentrations of beta endorphin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consent rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of spontaneous movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emotional status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptance of mandibular block vs maxillary infiltration
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PsAID9 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EPDS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of postpartum self-harm ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of recurrence of any mood episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum concentrations of interleukin-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distension and anatomical visualization of the stomach and proximal duodenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Score of angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac function class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-thrombotic syndrome (PTS)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of unintentional tube dislodgment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of goal calories received
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained cessation of smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smoking cessation rate at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work ability index
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Sleep problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Complications during procedure
Endpoint domain: Adverse events/effects
Primary endpoint: incident hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement on the Leicester Cough Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in daily cough scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: predialysis beta(2)-microglobulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: postdialysis beta(2)-microglobulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: beta(2)-microglobulin reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive life perspective
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Global lifestyle
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of children who completed three doses of DTaP-IPV vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration to the completion of the third dose of vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall survival percentage at 20 years
Endpoint domain: Mortality/survival
Primary endpoint: Colorectal cancer-specific survival at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: CHD risk
Endpoint domain: Mortality/survival
Primary endpoint: Confidence in preventing asthma episodes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence in treating symptomatic episodes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of PIH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: outer-to-inner deposition ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: whole-body deposition percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: extrathoracic deposition percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Target Lesion Revascularisation (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of cerebral microbleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatal or irreversible events
Endpoint domain: Mortality/survival
Primary endpoint: waist-to-hip ratio (WHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of renal disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: post-operative pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance of solutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Kt/V values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Systolic and mean pulmonary artery pressure (PAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean aesthetic score at 1 year after loading
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: complications affected patients
Endpoint domain: Adverse events/effects
Primary endpoint: Oswestry disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: femoral fracture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total positivity rate for Spirometra spp. eggs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of deformed eggs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic ability using virtual vs. glass slides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetabular morphology assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of hips assessed by dynamic ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indeterminate results needing follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of AS
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in melanin content of the lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dyspnoea VAS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lar anxiety score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Morphine dose reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Relative bioavailability of fimasartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: dental mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cost-effectiveness of bimatoprost/timolol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effectiveness of bimatoprost/timolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health status improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of postmastectomy pain syndrome (PMPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Acute Mountain Sickness (AMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive touch-response for the hand quadrants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous threshold of the less-affected palm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic BP elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: diastolic BP elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in PFDI-20 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women reporting improvement in overall symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cotinine-validated abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: setting a quit date
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of propiverine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pathological acid reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: NAB (Non-Acid Reflux)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Predicted FEV1 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean viral load decline from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primary tumour control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Favorable neurological outcome
Endpoint domain: Mortality/survival
Primary endpoint: Sero-protective rates to poliovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum IgA responses to RV3-BB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: knowledge of tooth avulsion management
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUC0‐t(last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: C max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Estimated total insulin activity (GIR AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delivery of services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severity of chronic urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Major toxic effects requiring switch to intravenous pentamidine
Endpoint domain: Adverse events/effects
Primary endpoint: Instances of severe chemical hepatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Marked neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Access to debriefing information
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: poor outcome at 2 months
Endpoint domain: Mortality/survival
Primary endpoint: 1-year outcome
Endpoint domain: Mortality/survival
Primary endpoint: Risk for clinical stroke events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Graft survival at 1 and 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of biopsy documented rejection in the first 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Estimated glomerular filtration rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Emotional upset due to pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: positive perceptions of exercise
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scapholunate distance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chlamydia screening test rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chlamydia infections detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: overall success rate of medical management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 20-year overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of upper limb function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge acquisition about opioid medications
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: debris and smear layer scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days needed to regain birthweight
Endpoint domain: Mortality/survival
Primary endpoint: Respiratory muscle strength (P(Imax))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal expiratory pressure (P(Emax))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory rate (RR)/tidal volume (V(T)) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Precision for fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of plethysmography vs hydrodensitometry
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Axis Opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size and Decentration of ACCC and PCCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extubation MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: recovery profile
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of adolescents who knew their HIV status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mask leak during one-person ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance quality scores of correct head positioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of airway manoeuvres
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Progression-Free Survival (PFS) hazard ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 to 5 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Gametocyte prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average duration of gametocyte carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Left Ventricular Global Longitudinal Strain (LV GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acupuncture sensation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete heart block
Endpoint domain: Adverse events/effects
Primary endpoint: total nitrite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency Department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Facility costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Residual gastric content volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric pH > 2.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Electrical pain tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posterior delta and alpha source activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of respiratory infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Conversion to PSA more than 4 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnosis of cancer within 2 years of conversion
Endpoint domain: Mortality/survival
Primary endpoint: Time to deliver a shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate pad placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diarrhoea-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Agreement between smartphone ophthalmoscopy and slit-lamp examination for VCDR estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost savings per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clearance of CIN2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in log10 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean root coverage (MRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complete root coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: clinically significant erythema score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: incidence of very slight erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: adherence rate of patches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: severe asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of planned intervention visits occurred
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of movement during induction of general anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Successful insertion rate of C-LMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Emergence of airway reflex
Endpoint domain: Adverse events/effects
Primary endpoint: Use of unscheduled healthcare
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: overall severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vocal effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: laryngeal tightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trans-pulmonary balances (TPB) of TxB2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of prostanoids (6‐keto‐PGF1alpha and TxB2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free linoleic acid fraction in arterial blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombocytopenia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: proportion of patients who failed the voiding trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: WOMAC pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes